Zanubrutinib

Active substance Zanubrutinib
Domain Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Aggressive non-Hodgkin's lymphoma
Extended indication Mantelcel non-hodgkin lymfoom Waldenström's macroglobulinaemia (WM) Chronische Lymfatische Leukemie (CLL)

Product

Proprietary name BGB-3111
Manufacturer BeiGene
Mechanism of action Tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Orphan drug Yes
Registration phase Clinical trials

Therapeutic value

Current treatment options Zal competitief zijn met ibrutinib.
Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

27 - 79

Market share is generally not included unless otherwise stated.

References Pakketadvies ibrutinib
Additional comments De verwachting is dat zanubrutinib de concurrentie aan zal gaan met ibrutinib. De inschatting van het patiëntvolume in het ''pakketadvies ibrutinib'' bij patiënten met CLL betrof 27 tot 79 mogelijke patiënten die in aanmerking komen.

Expected cost per patient per year

Additional comments Huidige Lijstprijs ibrutinib x Maximaal gebruik per jaar: €69.839. Dit betreft alleen Ibrutinib. Voor de indicatie 1e lijns Chronische lymfatische leukemie (CLL) wordt onderhandeld over een financieel arrangement en zit het geneesmiddel in de sluis.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions B-cell lymphoma; Waldenstrom's macroglobulinaemia
References adisinsight
Additional comments Lopende fase 3 studies.

Other information

There is currently no futher information available.